Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$13.52 - $21.46 $25,688 - $40,774
-1,900 Reduced 24.05%
6,000 $100,000
Q3 2022

Nov 14, 2022

SELL
$10.5 - $22.01 $48,300 - $101,246
-4,600 Reduced 36.8%
7,900 $135,000
Q2 2022

Aug 15, 2022

BUY
$8.7 - $20.18 $108,749 - $252,250
12,500 New
12,500 $137,000

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $58.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Sandia Investment Management LP Portfolio

Follow Sandia Investment Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandia Investment Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Sandia Investment Management LP with notifications on news.